GENZYME BUYS INTO CELTRIX' TGF-BETA-2 NEURODEGENERATIVE TREATMENT WITH $60 MIL.
Executive Summary
GENZYME BUYS INTO CELTRIX' TGF-BETA-2 NEURODEGENERATIVE TREATMENT WITH $60 MIL. investment that includes equity in the Palo Alto, Calif. biopharmaceutical R&D firm, milestone payments and R&D work, Genzyme announced June 27. Recombinant transforming growth factor-beta-2 (TGF-beta-2, or BetaKine), Celtrix' lead product, will be developed for tissue growth promotion in chronic wounds, for multiple sclerosis treatment and other applications such as dermal wound healing.